Biology Reference
In-Depth Information
Houslay MD, Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that
orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:
1-18
Houslay MD, Adams DR (2010) Putting the lid on phosphodiesterase 4. Nat Biotechnol 28:38-40
Houslay MD, Schafer P, Zhang KY (2005) Keynote review: phosphodiesterase-4 as a therapeutic
target. Drug Discov Today 10:1503-1519
Houslay MD, Baillie GS, Maurice DH (2007) cAMP-Specific phosphodiesterase-4 enzymes in
the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP
signaling. Circ Res 100:950-966
Huston E, Pooley L, Julien P, Scotland G, McPhee I, Sullivan M, Bolger G, Houslay MD (1996)
The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in
transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct
kinetics of inhibition by the antidepressant rolipram. J Biol Chem 271:31334-31344
Jacobitz S, McLaughlin MM, Livi GP, Burman M, Torphy TJ (1996) Mapping the functional
domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic
activity and rolipram binding. Mol Pharmacol 50:891-899
Jin SL, Conti M (2002) Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential
for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A 99:7628-7633
Jin SL, Richard FJ, Kuo WP, D'Ercole AJ, Conti M (1999) Impaired growth and fertility of cAMP-
specific phosphodiesterase PDE4D-deficient mice. Proc Natl Acad Sci U S A 96:11998-12003
Ke H, Wang H (2007) Crystal structures of phosphodiesterases and implications on substrate
specificity and inhibitor selectivity. Curr Top Med Chem 7:391-403
Kovala T, Sanwal BD, Ball EH (1997) Recombinant expression of a type IV, cAMP-specific
phosphodiesterase: characterization and structure-function studies of deletion mutants.
Biochemistry 36:2968-2976
Kranz M, Wall M, Evans B, Miah A, Ballantine S, Delves C, Dombroski B, Gross J, Schneck J,
Villa JP, Neu M, Somers DO (2009) Identification of PDE4B Over 4D subtype-selective
inhibitors revealing an unprecedented binding mode. Bioorg Med Chem 17:5336-5341
Laux G, Becker T, Kuhne G, Lesch KP, Riederer P, Beckmann H (1988) Clinical and biochemical
effects of the selective phosphodiesterase inhibitor rolipram in depressed inpatients controlled
by determination of plasma level. Pharmacopsychiatry 21:378-379
Lee ME, Markowitz J, Lee JO, Lee H (2002) Crystal structure of phosphodiesterase 4D and
inhibitor complex(1). FEBS Lett 530:53-58
Lehnart SE, Wehrens XH, Reiken S, Warrier S, Belevych AE, Harvey RD, Richter W, Jin SL,
Conti M, Marks AR (2005) Phosphodiesterase 4D deficiency in the ryanodine-receptor com-
plex promotes heart failure and arrhythmias. Cell 123:25-35
Li YF, Huang Y, Amsdell SL, Xiao L, O'Donnell JM, Zhang HT (2009) Antidepressant- and
anxiolytic-like effects of the phosphodiesterase-4 inhibitor rolipram on behavior depend on
cyclic AMP response element binding protein-mediated neurogenesis in the hippocampus.
Neuropsychopharmacology 34:2404-2419
Lipworth BJ (2005) Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary
disease. Lancet 365:167-175
Liu S, Laliberte F, Bobechko B, Bartlett A, Lario P, Gorseth E, Van Hamme J, Gresser MJ, Huang
Z (2001) Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors.
Biochemistry 40:10179-10186
Lorimer D, Raymond A, Walchli J, Mixon M, Wallace E, Barrow A, Grice R, Burgin A, Stewart L
(2009) Gene composer: database software for protein construct design, codon engineering, and
gene synthesis. BMC Biotechnol 9:36
Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the
development of specific therapeutic agents. Pharmacol Ther 109:366-398
Lynch MJ, Baillie GS, Mohamed A, Li X, Maisonneuve C, Klussmann E, van Heeke G, Houslay
MD (2005) RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodi-
esterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated
